ICG-122 is under clinical development by ICell Gene Therapeutics and currently in Phase I for T-Cell Lymphomas. According to GlobalData, Phase I drugs for T-Cell Lymphomas have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ICG-122’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Gene therapy is under development for the treatment of CD4 positive leukemias including peripheral T-cell leukemias, T-cell prolymphocytic leukemia, adult T-cell leukemia, T-cell large granular lymphocytic leukemia and T cell acute lymphoblastic leukemia T-ALL and CD4 positive lymphomas including peripheral T-cell lymphoma, sezary syndrome, cutaneous T-cell lymphoma, angioimmunoblastic T-cell lymphoma adult T-cell lymphoma, relapsed and refractory acute myeloid leukemia and chronic myelomonocytic leukemia. The therapy comprises of T cells genetically modified by lentiviral transduction to express a chimeric antigen receptor (CAR) targeting the antigen CD4. It was also under development for the treatment of acute myeloid leukemia and relapsed or refractory multiple myeloma.
ICell Gene Therapeutics overview
iCell Gene Therapeutics (ICell Gene) is a biotechnology company. The company research and develops chimeric antigen receptor engineered cells that target multiple types of cancer with poor prognoses. It offers CARvac, T-cell targeted, compound CAR’s and universal CAR’s. ICell Gene offers orphan drug designation for five CARs in multiple myeloma, peripheral t-cell lymphoma, acute myeloid leukemia, b-acute lymphocytic leukemia and t-cell acute lymphocytic leukemia. The company creates novel CAR constructs and CAR enhancing technologies for applicability of transduced T and NK cells. It has operations in the US and China. ICell Gene is headquartered in Brookhaven, New York, the US.
For a complete picture of ICG-122’s drug-specific PTSR and LoA scores, buy the report here.